Evaluation of an enzyme immunoassay for hepatitis C virus antibody detection using a recombinant protein derived from the core region of hepatitis C virus genome

Página do item simplificado
dc.contributor.authorLopes, Epa [UNIFESP]
dc.contributor.authorGranato, Celso Francisco Hernandes [UNIFESP]
dc.contributor.authorLanzoni, Valeria Pereira [UNIFESP]
dc.contributor.authorGranero, L [UNIFESP]
dc.contributor.authorParanhos-Baccala, G
dc.contributor.authorTomiyama, H [UNIFESP]
dc.contributor.authorSilva, Aeb [UNIFESP]
dc.contributor.authorFerraz, Maria Lucia Cardoso Gomes [UNIFESP]
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionInstituto BioMérieux
dc.date.accessioned2015-06-14T13:25:07Z
dc.date.available2015-06-14T13:25:07Z
dc.date.issued2000-10-01
dc.description.abstractThis study was undertaken to evaluate an enzyme immunoassay (EIA) for hepatitis C virus antibody detection (anti-HCV), using just one antigen. Anti-HCV EIA was designed to detect anti-HCV IgG using on the solid-phase a recombinant C22 antigen localized at the N-terminal end of the core region of HCV genome, produced by BioMérieux. The serum samples diluted in phosphate buffer saline were added to wells coated with the C22, and incubated. After washings, the wells were loaded with conjugated anti-IgG, and read in a microtiter plate reader (492 nm). Serum samples of 145 patients were divided in two groups: a control group of 39 patients with non-C hepatitis (10 acute hepatitis A, 10 acute hepatitis B, 9 chronic hepatitis B, and 10 autoimmune hepatitis) and a study group consisting of 106 patients with chronic HCV hepatitis. In the study group all patients had anti-HCV detected by a commercially available EIA (Abbott®), specific for HCV structural and nonstructural polypeptides, alanine aminotransferase elevation or positive serum HCV-RNA detected by nested-PCR. They also had a liver biopsy compatible with chronic hepatitis. The test was positive in 101 of the 106 (95%) sera from patients in the study group and negative in 38 of the 39 (97%) sera from those in the control group, showing an accuracy of 96%. According to these results, our EIA could be used to detect anti-HCV in the serum of patients infected with hepatitis C virus.en
dc.description.affiliationUniversidade Federal de São Paulo (UNIFESP) Escola Paulista de Medicina
dc.description.affiliationInstituto BioMérieux
dc.description.affiliationUnifespUNIFESP, EPM
dc.description.sourceSciELO
dc.format.extent717-720
dc.identifierhttp://dx.doi.org/10.1590/S0074-02762000000500019
dc.identifier.citationMemórias do Instituto Oswaldo Cruz. Instituto Oswaldo Cruz, Ministério da Saúde, v. 95, n. 5, p. 717-720, 2000.
dc.identifier.doi10.1590/S0074-02762000000500019
dc.identifier.fileS0074-02762000000500019.pdf
dc.identifier.issn0074-0276
dc.identifier.scieloS0074-02762000000500019
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/1041
dc.language.isoeng
dc.publisherInstituto Oswaldo Cruz, Ministério da Saúde
dc.relation.ispartofMemórias do Instituto Oswaldo Cruz
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjecthepatitis C virus (HCV)en
dc.subjectanti-HCV antibodyen
dc.subjectenzyme immunoassayen
dc.titleEvaluation of an enzyme immunoassay for hepatitis C virus antibody detection using a recombinant protein derived from the core region of hepatitis C virus genomeen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
S0074-02762000000500019.pdf
Tamanho:
44.89 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
Em verificação - Geral